Discover the extensive experience of our team in the realm of bioanalytical assay development, validation, and sample analysis. Join Vito Saccente and John Ryan in this insightful video as they shed light on our comprehensive support, spanning the entire spectrum from early drug evaluation to clinical trials.
Filmed at AAPS 2023 PharmSci 360, this video showcases how our flexibility and agility align perfectly with the specific demands of our clients.
🎥. To gain valuable insights into Resolian's commitment and global expertise, watch the video
Join CEO Patrick Bennett in an exclusive video where he delves into the mission, vision, and values that drive us. Filmed at AAPS 2023 PharmSci 360, this insightful discussion highlights our commitment to excellence in the analytical and bioanalytical space.
Our journey has been marked by its evolution from Alliance Pharma Inc. and Drug Development Solutions Ltd. Patrick Bennett shares strategic insights into our recent expansion into the Chinese market. In this interview, Pat elaborates on the distinctive expertise embedded within each of Resolian's four global laboratories, emphasizing the synergy and harmonization meticulously maintained across the organization.
🎥 Learn more about Resolian's global endeavours by watching the video
Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali MEd pharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.
Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022), today announced they will be operating under the new name Resolian — fully integrating the companies into one organization. This brings together the companies’ established bioanalytical laboratories and experts in the U.S., U.K., and most recently in Australia, as Resolian continues to expand and support the growing need for small and large molecule bioanalytical and analytical services globally.
MALVERN, Pa.; December 7, 2022 (Business Wire) – Alliance Pharma (Alliance), a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its new 20,000-square-foot (1,858-square-meter) bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia.
The new Australia facility, which the company announced plans for earlier this summer, includes an expansive lab to provide much-needed small and large molecule bioanalytical services for a region with limited choices for bioanalytical support.
MALVERN, Pa.; July 13, 2022 (Business Wire) – Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc. (KKR) (NYSE:KKR), a leading global investment firm, are equal shareholders in the combined company.
MALVERN, Pa., April 29, 2022 /PRNewswire/ -- 
This week, AlliancePharma (Malvern, PA) announced their go-live of PSQuote together with CLD Partners (Front Royal, VA). PSQuote is a newly developed professional services quoting application built on the Salesforce platform (PSQuote is a wholly-owned division of CLD Partners). AlliancePharma will use the tool to enhance and elevate their sales cycle, delivering a better customer sales experience--from quote to service delivery. CLD Partners has engaged with AlliancePharma since June 2021, for FinancialForce implementation services, and this new deployment is the next step in a growing business relationship. . .
Malvern, PA, March 25, 2022 - Alliance Pharma, a leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, announces that Patrick Bennett has been named Chief Executive Officer. Bennett has more than 30 years of experience in the industry, including 25 years in leadership roles at various bioanalytical contract research organizations, most recently as Vice President, Strategy and . . .
WELLESLEY, MA, November 18, 2021 /PRNewswire/ -- Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, has announced an investment in Alliance Pharma (“Alliance”), a global leader in large and small molecule bioanalytical services. Headquartered in Malvern, PA., Alliance provides a full suite of discovery bioanalytical, DMPK, regulated bioanalysis, biomarker, LC-MS/MS, immunoassay, and cell and gene therapy assays. These capabilities support preclinical-through-Phase 4 studies run by a global customer base comprised of leading pharma and biotech companies.
